A Study of High Inlet Flow Rate Hematopoietic Progenitor Cell Collection Using the Fenwal Amicus

Overview

About this study

The purpose of this study is to perform a paired comparison of CD34+ cell and lymphocyte yield, as well as cross-cellular contamination, on the same patient/donor using the 85 ml/min high flow rates versus the standard speeds of 65 ml/min for pre WBC of > 35 x109/L or 90 ml/min for pre WBC of ≤ 35 x109/L.  Quantities of CD34+cells, lymphocytes, white blood cells, red blood cells, and platelets in the products would be compared.  In addition, collection efficiency of CD34+ cells and lymphocytes would be compared.  The yields and collection efficiencies would be used to judge the effect of the high flow rates.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Adult patients or allogeneic donors requiring Hematopoietic Progenitor Cell collection

Exclusion Criteria

  • Pediatric patients

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Jeffrey Winters, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions